Neumora Therapeutics Inc (NMRA) Financial

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 110 full-time employees. The company went IPO on 2023-09-15. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.